Susan Ashton

Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic–Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104

Peter Ballard, James W T Yates, S. Ashton, 2016, Molecular Cancer Therapeutics.

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.

Peter Ballard, Simon J Brown, Nathaniel G. Martin, 2014, Journal of medicinal chemistry.

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).

Matthew Grist, M Raymond V Finlay, Richard A Ward, 2013, Journal of medicinal chemistry.